People · Operator
Named in public records as an officer, director or promoter · active 2011–2013 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Daktari Diagnostics, Inc. | — | Biotechnology | Series B | $76.3M | $893.0M | 2011 |
Christopher Earl at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Earl on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Rubin | 1 | 11 |
| Aaron Sandoski | 1 | 7 |
| Stanley Lapidus | 1 | 7 |
| Roger Kitterman | 1 | 5 |
| Edward Roberts | 1 | 3 |
| William Rodriguez | 1 | 2 |
| Thierry Bernard | 1 | 2 |
| Michael Crowley | 1 | 1 |
| Peter Kaspar | 1 | 1 |
| Donald Hawthorne | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.